Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

GSK's Exdensur (depemokimab) wins China approval for chronic rhinosinusitis with nasal polyps treatment
Antibody, respiratory disease, monoclonal antibody, chronic rhinosinusitis with nasal polyps, IL-5 antagonist, ultra-long-acting biologic - Read more

Shionogi lands US BARDA contract for Fetroja antibiotic manufacturing, $482M potential value
Government contract, infectious disease, manufacturing, antibiotic - Read more

Akari Therapeutics, WuXi XDC partner on ADC development and manufacturing for novel cancer treatment
Manufacturing agreement, oncology, antibody-drug conjugate, drug development - Read more

ProQR Therapeutics, Ginkgo Bioworks partner on AI-enabled drug discovery with strategic equity investment
Research collaboration, AI/ML, RNA editing, drug discovery, equity investment - Read more

Astellas, Dyno Therapeutics exercise option on AI-designed AAV capsid, triggering $15M payment
Licensing deal, gene therapy, AI/ML, milestone payments - Read more

ATLATL, Daiichi Sankyo partner to identify APAC biotech R&D platforms and accelerate innovative science transformation
Research collaboration, drug discovery, R&D, small molecule, gene therapy - Read more

Cosette Pharmaceuticals acquires SYMPAZAN and six branded products from Assertio Holdings
Acquisition, rare disease, neurological, commercialization - Read more

JW Pharmaceutical, Gan & Lee license-in agreement for GLP-1 receptor agonist bofanglutide, $81.1M deal
Licensing deal, GLP-1 receptor agonist, milestone payments, tiered royalties - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Ascendis Pharma's TransCon CNP (navepegritide) combo shows positive Ph2 results for achondroplasia in children
Protein therapy, genetic disorder, growth hormone, achondroplasia, combination therapy - Read more

Jeito Capital raises $1.2B fund, investing in European clinical-stage drugmakers
Venture capital, clinical-stage, biopharma investor - Read more

Sidewinder Therapeutics raises $137M Series B, advancing precision bispecific ADCs
Oncology, antibody-drug conjugate, bispecific, preclinical, platform technology - Read more

Life Biosciences raises $80M Series D, cellular rejuvenation therapies for aging diseases
Cellular rejuvenation, aging diseases, gene therapy, neurological, clinical-stage, platform technology - Read more

Forte Biosciences raises $150M public offering, autoimmune disease clinical development funding
Autoimmune, clinical-stage, biopharmaceutical - Read more

Polyrizon raises $3.5M registered direct/private placement, intranasal protective solutions development
Preclinical, intranasal delivery, protective solutions, biotechnology - Read more

ReAlta Life Sciences raises $40M funding, advancing pegtarazimod for inflammation-driven diseases
Clinical-stage, neurological, peptide therapy, inflammatory diseases - Read more

Biogen settles investor lawsuit over misleading messaging on failed Alzheimer's drug Aduhelm FDA approval
Monoclonal antibody, neurological, financial, regulatory - Read more

Garda Therapeutics to acquire Assertio Holdings for $125.1M in cash plus contingent value rights
Pharmaceutical portfolio, pain management, strategic, major transaction - Read more

Gilead Sciences pauses M&A after acquiring Arcellx, Ouro Medicines, and Tubulis within six weeks
CAR-T, oncology, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Novavax shareholder Shah Capital opposes CEO pay package, demands leadership overhaul amid declining stock performance
Protein subunit vaccine, infectious disease, operational, strategic - Read more

AbbVie sues to narrow 340B patient eligibility definition, claiming hospitals abuse discount program
Drug pricing, healthcare access, strategic, regulatory - Read more

FDA issues warning letter to Medline over defective heart syringes causing safety hazards
Medical device, cardiovascular, regulatory, operational, financial - Read more

Soleno Therapeutics withdraws EU filing for Prader-Willi drug Viokat ahead of $2.9B Neurocrine acquisition
Small molecule, rare disease, strategic, major transaction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here